Drug Trial Radar · NCT01762046
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,033
Actual
Start
Jan 2008
Primary completion
Dec 2015
Study completion Dec 2025
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Brigham and Women's Hospital; Joslin Diabetes Center; Broad Institute of MIT and Harvard
- First posted
- Jan 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.
Conditions
- Diabetes Mellitus, Type 2
Interventions
GlipizideDrug
MetforminDrug
Oral Glucose Tolerance TestOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to GenotypeTime frame: 0, 30, 60, 90, 120, 180 and 240 minutes post 5mg oral glipizide dose, Day 1 (visit 1)
- Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to GenotypeTime frame: 0,30,60,90,120,180 and 240 minutes on Day 1 (Visit 1)
- Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2Time frame: Day 1 (Visit 1) and Day 8 (Visit 2)
- Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2Time frame: Day 1 (Visit 1) and Day 8 (Visit 2)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.